Immunocore announces the dosing of the first patient for chronic Hepatitis B with the ImmTAV® bispecific molecule

Immunocore Holdings Plc today announces the dosing of the first patient in the first-in-human clinical trial of IMC- 109V to treat patients with chronic hepatitis B (HBV) infection. Wholly owned IMC-I109V is the first candidate in development using Immunocore’s immune-mobilizing monoclonal T cell receptors against virus (ImmTAV®) platform to enter clinical trials. The trial is an open-label study to assess the safety, antiviral activity, and pharmacokinetics of IMC-I190V in non-cirrhotic, hepatitis B antigen-negative, and virally suppressed HLA-A*02:01 positive patients with chronic Hepatitis B.

Publish Date: 18-05-2021   Source: Immunocore Holdings Plc.

Chronic hepatitis B infection is defined as HBsAg in the serum for six months. HBeAg and HBV DNA (measured using a polymerase chain reaction (PCR) assay) are viral replication and infectivity markers, whereas HBsAg is a hepatitis B viral infection marker. Cirrhosis, liver failure, hepatocellular carcinoma, and death are severe complications of chronic infection. HBV DNA can be found in the serum without HBeAg in a small percentage of patients. The “precore” mutant in these patients prevents completion and excretion of the “e” antigen despite active HBV DNA replication and is linked to progressive liver disease.

• The risk for developing chronic hepatitis B after acute HBV infection is age-dependent; approximately 90% of infants become chronically infected, whereas only. Less than 5% of adults experience chronic illness.

However, the current chronic hepatitis B treatment market share, market uptake, and attribute analysis concerning the most potential emerging therapies (Entecavir, Ibrutinib, (PEG-IFN) alfa-2a, Tenofovir disoproxil fumarate, Telbivudine, ABT333, Peginterferon alfa-2b, Besifovir, DA-2802, etc.) has provided under the market outlook section of the study covering 8 MM countries; The United States, EU5 (Germany, Spain, France, Italy, UK) Japan and China.

In terms of pharmacologic therapies, several pharmaceutical products are being approved and under different phases of development for chronic hepatitis B treatment. The key companies in to advance stage of results are Bristol-Myers Squibb, Janssen, Roche, Gilead Sciences, Novartis, AbbVie, Xiamen Amoytop Biotech, IlDong Pharmaceutical, GlaxoSmithKline, Dong-A ST, etc. targeting HBV.

Based on solid domain and business knowledge, Thelansis Knowledge Partners has published the market outlook forecast report on Chronic Hepatitis B to provide a clear understanding of disease area background, epidemiology, current and future competitions, the country-specific standard of care, and the complete market forecast for 2021 to 2032.